CureVac Advances mRNA Immunotherapy for Lung Cancer

CureVac has received clearance from the U.S. FDA for its Investigational New Drug (IND) application, permitting the initiation of a Phase 1 clinical trial for its mRNA-based precision immunotherapy, CVHNLC, targeting squamous non-small cell lung cancer (sqNSCLC). This investigational therapy uses proprietary tumor epitopes and will be tested in combination with pembrolizumab to enhance targeted anti-tumor immune responses.

The upcoming phase 1 trial will explore CVHNLC's safety and tolerability, focusing on dose escalation in patients with advanced sqNSCLC. This milestone represents a significant advancement in CureVac's oncology pipeline, with patient treatments anticipated to commence in the latter half of 2025.